Quantcast
Home > Quotes > RTRX

Retrophin, Inc. Common Stock (RTRX) Quote & Summary Data

RTRX 
$28.96
*  
0.89
3.17%
Get RTRX Alerts
*Delayed - data as of Sep. 18, 2018  -  Find a broker to begin trading RTRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RTRX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 28.97 / $ 27.90
Share Volume
323,680
50 Day Avg. Daily Volume
400,694
Previous Close
$ 28.07
52 Week High / Low
$ 33 / $ 20.0901
Market Cap
1,183,282,837
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
323,680
50 Day Avg. Daily Volume:
400,694

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.03

Trading Range

The current last sale of $28.96 is 44.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 28.97 $ 33
 Low: $ 27.90 $ 20.0901

Company Description (as filed with the SEC)

Those statements in the following discussion that are not historical in nature should be considered to be forward looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward looking statements due to a number of factors, including those discussed in the "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" set forth elsewhere in this Annual Report. Overview We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. Our approach centers on our pipeline, featuring clinical-stage assets and pre-clinical discovery programs targeting rare diseases with significant unmet medical needs. Our research and development efforts are supported by revenues from our commercialized products, Chenodal┬«, Cholbam┬« and Thiola┬«.  ... More ...  


Risk Grade

Where does RTRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 28.26
Open Date:
Sep. 18, 2018
Close Price:
$ 28.96
Close Date:
Sep. 18, 2018

Consensus Recommendation

Analyst Info